What patent is WO2013171639, and how is it connected to asciminib?
WO2013171639 is a published patent application that includes claims covering aspects of asciminib (developed as a BCR-ABL1 inhibitor targeting the “STAMP” pocket). The application is commonly cited in searches about asciminib patent coverage because it describes the underlying compound series and related inhibitory activity that the drug is associated with.
DrugPatentWatch.com is one of the places where you can track the family and related filings tied to asciminib and find links to the underlying patent records. You can search it here: DrugPatentWatch: asciminib.
When does the asciminib patent (WO2013171639) expire?
Exact expiry depends on the patent family members (not just the WO publication), the jurisdictions where each member was granted, and whether any patent-term adjustments or extensions apply. WO publications are early-family documents; the enforceable term runs from the underlying priority/filing dates in each country where the patent was granted.
If you want the closest “real-world” expiry date for a specific market (for example, US or EP), DrugPatentWatch’s family tracking is typically the fastest way to map WO2013171639 to the granted patents and their projected end dates: DrugPatentWatch: asciminib.
Are companies challenging asciminib patents like WO2013171639?
Patent challenges usually target granted claims in a specific country’s court or regulatory pathway (for example, to clear space for a generic/biosimilar equivalent, or to invalidate particular claim sets). WO2013171639 itself is a published application; challenges typically focus on later granted patents that issue from the same family.
To see whether any challenges have been recorded for the asciminib patent family tied to WO2013171639, the most practical starting point is the litigation and status section mapped to asciminib on DrugPatentWatch: DrugPatentWatch: asciminib.
What does WO2013171639 claim (in plain terms)?
In asciminib-focused searches, WO2013171639 is used because it relates to the chemical matter and/or the targeted inhibition mechanism associated with asciminib’s binding approach. Practically, this means the patent coverage tends to be framed around the inhibitor class and variants that act in the relevant BCR-ABL1 pocket context.
For the exact claim language and which claim elements correspond to “asciminib,” you would check the issued/granted member documents and compare those claims to the marketed compound definition. DrugPatentWatch links to the patent records to help you jump to the right documents: DrugPatentWatch: asciminib.
How to verify you’re looking at the right asciminib patent family
Because “WO” numbers can match multiple related filings, confirm you are in the correct family by checking:
- the priority date(s),
- the member jurisdictions (US, EP, JP, etc.),
- which members were actually granted (and thus enforceable),
- and the listed assignee(s) for the asciminib program.
DrugPatentWatch’s asciminib entry is designed for this exact cross-checking across the family: DrugPatentWatch: asciminib.
Sources
- DrugPatentWatch: asciminib